Holmes led the efforts that resulted in the first ever clinical candidate of a genome editing-based therapy and has extensive experience in the genome editing of T-cells, hematopoietic stem cells, and hepatocytes. Holmes was the Chief Scientific Officer of Ambys Medicines, and he also held various leadership positions at Sangamo Therapeutics, Inc., including Senior Vice President and Chief Technology Officer.ĭr. He has an accomplished track record of translating genome engineering technologies to product candidates as evidenced by leading ten therapeutic programs across ex vivo and in vivo therapies. Holmes has more than 20 years of experience working on the development and clinical translation of genome editing- and gene therapy-based approaches. Michael Holmes has joined Tessera Therapeutics as its Chief Scientific Officer to lead the development of novel technologies and transformative therapies. Michael Holmes, Ph.D., Chief Scientific Officerĭr. We’re thrilled that our research will be led by Mike Holmes, whose previous roles included spearheading development of the industry’s first gene editing platform and therapeutic candidates.” “To realize this goal, we’re building the field’s top team across all levels and functions of our organization. “We set out to revolutionize the field of genetic medicine by pioneering Gene Writing technology that can unlock the therapeutic potential of engineering DNA and address the short-comings of today’s gene therapy and gene editing approaches,” said Dr. “Their leadership, experiences, and mindsets will be critical in helping to realize our aspirations in genetic medicine, attract and maintain the best talent, and develop our pipeline of Gene Writer candidates to cure and prevent severe diseases.” Geoffrey von Maltzahn, CEO and Co-Founder of Tessera and General Partner, Flagship Pioneering. “Michael, Iain, and Bec are invaluable additions to our Tessera team and our mission to cure disease by writing in the code of life,” said Dr. In addition to the three executive appointments, Rebecca Wais, Ph.D., JD, Vice President, Intellectual Property and Legal Affairs, and Ian O’Reilly, Vice President, Head of GMP Quality, recently joined the Tessera team to bolster the company’s internal legal and manufacturing capabilities. Jacob Rubens, Ph.D., Co-Founder of Tessera and Senior Principal, Flagship Pioneering, has transitioned from Tessera’s Chief Scientific Officer to Chief Innovation Officer. CAMBRIDGE, Mass.-( BUSINESS WIRE)-Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™ technology, today announced the expansion of its executive leadership team with appointments of Michael Holmes, Ph.D., Chief Scientific Officer, Iain McFadyen, Ph.D., Chief Data Officer, and Becky Lillie, Chief Human Resources Officer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |